Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Gage

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Journal of Thrombosis and Haemostasis : JTH|July 30, 2008
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsP A Lenzini, G R Grice, P E Milligan, et al.
Clinical Pharmacology and Therapeutics|February 29, 2008
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinB F Gage, C Eby, J A Johnson, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
Blood|March 6, 2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsNita A Limdi, Mia Wadelius, Larisa Cavallari, et al.
Stroke|February 27, 2023
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual WorkshopAlan S Go, Sana M Al-Khatib, Patrice Desvigne-Nickens, et al.
JAMA|October 4, 2017
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
JAMA|September 4, 2019
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
Clinical Pharmacology and Therapeutics|April 9, 2010
Integration of genetic, clinical, and INR data to refine warfarin dosingP Lenzini, M Wadelius, S Kimmel, et al.
Thrombosis and Haemostasis|December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyBenjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
The New England Journal of Medicine|November 21, 2013
A pharmacogenetic versus a clinical algorithm for warfarin dosingStephen E Kimmel, Benjamin French, Scott E Kasner, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Journal of Thrombosis and Haemostasis : JTH|July 30, 2008
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patientsP A Lenzini, G R Grice, P E Milligan, et al.
Clinical Pharmacology and Therapeutics|February 29, 2008
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarinB F Gage, C Eby, J A Johnson, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
Blood|March 6, 2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsNita A Limdi, Mia Wadelius, Larisa Cavallari, et al.
Stroke|February 27, 2023
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual WorkshopAlan S Go, Sana M Al-Khatib, Patrice Desvigne-Nickens, et al.
JAMA|October 4, 2017
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
JAMA|September 4, 2019
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical TrialBrian F Gage, Anne R Bass, Hannah Lin, et al.
Clinical Pharmacology and Therapeutics|April 9, 2010
Integration of genetic, clinical, and INR data to refine warfarin dosingP Lenzini, M Wadelius, S Kimmel, et al.
Thrombosis and Haemostasis|December 22, 2011
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapyBenjamin D Horne, Petra A Lenzini, Mia Wadelius, et al.
The New England Journal of Medicine|November 21, 2013
A pharmacogenetic versus a clinical algorithm for warfarin dosingStephen E Kimmel, Benjamin French, Scott E Kasner, et al.
Pageof 15